Voisard Asset Management Group, Inc. Viridian Therapeutics, Inc.\De Transaction History
Voisard Asset Management Group, Inc.
- $205 Billion
- Q2 2024
A detailed history of Voisard Asset Management Group, Inc. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Voisard Asset Management Group, Inc. holds 100 shares of VRDN stock, worth $2,206. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 100
-0.0%
Holding current value
$2,206
Previous $1.75 Million
25.7%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VRDN
# of Institutions
149Shares Held
60.7MCall Options Held
134KPut Options Held
238K-
Black Rock Inc. New York, NY4.77MShares$105 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.92MShares$86.6 Million1.68% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$85.7 Million5.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.35MShares$73.8 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx3.31MShares$73 Million0.85% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $880M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...